ACAD Q3 2023 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$212M+62.0% YoY

Gross Profit

$197M93.1% margin

Operating Income

-$58M-27.3% margin

Net Income

-$65M-30.8% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+28.1%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$59M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$633M

Total Liabilities

$270M

Stockholders' Equity

$362M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$212M	$131M	+62.0%
Gross Profit	$197M	$129M	+53.3%
Operating Income	-$58M	-$31M	-87.2%
Net Income	-$65M	-$27M	-139.8%